First published data on our development program, MosaiQ™

Posted

At the 2013 Annual Meeting for AABB, Quotient presented two posters of the first published results from our development program, MosaiQ™.  The first poster, which had been selected by AABB as a "Top Poster" and entitled "Evaluation of a Novel Serology-Based Platform for Irregular Blood Group Antibody Identification (MosaiQ™)", presented data from a 1,000 sample study demonstrating the ability to identify irregular blood group antibodies using MosaiQ™. 

The second poster entitled "ABO and Rh Antigen Typinng of Red Blood Cells Using a Novel Serology Based Multiplexed Protein Microarray Platform (MosaiQ™)" presented data from a study using 1,022 samples demonstrated the feasibility of the MosaiQ™ platform as an antigen typing platform.

In both studies results were compared and correlated to column agglutination technology.

There will be several more scientific presentations on MosaiQ™ in the next few months.

Quotient Puts the CE in CompEtency

Posted

Quotient has launched an e-learning website powered by beLearningTM www.bcw.edu/qcases where the customer can access Continuing Education case studies, specifically designed to synchron...

Read More »

Complying with CAP TRM.31450

Posted

Both CMS (42 CFR 493.1281) and the College of American Pathologists (TRM.31450 & COM.04250) require laboratories that use more than one method of testing a given analyte to have a system in pla...

Read More »

Get Answers Here